Financials in USD. Standardized financial statements.
A compact view of how Augmedix, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue? | $44.85M | $30.93M | $22.16M | $16.48M | $14.11M | $10.82M |
| Revenue Growth? | +45.0% | +39.6% | +34.5% | +16.8% | +30.4% | 0.0% |
| Cost of Revenue? | $23.33M | $16.98M | $12.16M | $9.69M | $9.43M | $10.03M |
| Gross Profit? | $21.53M | $13.95M | $10.01M | $6.79M | $4.68M | $785,917 |
| Gross Margin? | +48.0% | +45.1% | +45.1% | +41.2% | +33.2% | +7.3% |
| Operating Expenses? | $40.30M | $36.33M | $27.95M | $20.49M | $21.42M | $22.87M |
| Operating Income? | -$18.78M | -$22.37M | -$17.94M | -$13.69M | -$16.74M | -$22.92M |
| EBITDA? | -$15.68M | -$21.81M | -$14.47M | -$13.28M | -$14.74M | -$21.33M |
| Income Before Tax | -$19.03M | -$24.45M | -$17.85M | -$15.60M | -$18.50M | -$24.16M |
| Income Tax Expense | $145,000 | $0 | -$691,000 | $0 | $0 | $0 |
| Net Income? | -$19.17M | -$26.53M | -$17.16M | -$14.74M | -$22.36M | -$24.16M |
| EPS? | $-0.44 | $-0.71 | $-0.59 | $-0.56 | $-26.89 | $-12.25 |
| Diluted EPS? | $-0.44 | $-0.71 | $-0.59 | $-0.55 | $-26.89 | $-12.25 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality